ReviewJournal of ovarian research2026
Melatonin in ovarian function and dysfunction: Molecular mechanisms and therapeutic potential.
Review in Journal of ovarian research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Melatonin (MT) is a natural indoleamine compound. In addition to regulating sleep and circadian rhythms, MT exhibits antioxidative, anti-inflammatory, anti-apoptotic, and ovarian protective properties. Recent studies have shown that MT alleviates polycystic ovary syndrome (PCOS), premature ovarian insufficiency (POI), ovarian injury, and age-related ovarian function decline. This review establishes an integrated mechanistic model in which oxidative stress, mitochondrial dysfunction, inflammatory responses, and autophagic imbalance collectively contribute to the pathogenesis of ovarian disorders, while melatonin acts as a pleiotropic regulator that counteracts these interconnected pathological pathways. Furthermore, this review also discusses recent advances regarding the inhibitory effects of melatonin on ovarian tumors. Although MT shows considerable clinical promise, further research is needed to determine its optimal dosage, administration regimens, and therapeutic targets to facilitate its clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.